281 related articles for article (PubMed ID: 27539682)
1. Substance P is increased in patients with sickle cell disease and associated with haemolysis and hydroxycarbamide use.
Brandow AM; Wandersee NJ; Dasgupta M; Hoffmann RG; Hillery CA; Stucky CL; Panepinto JA
Br J Haematol; 2016 Oct; 175(2):237-245. PubMed ID: 27539682
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Nevitt SJ; Jones AP; Howard J
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD002202. PubMed ID: 28426137
[TBL] [Abstract][Full Text] [Related]
3. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
[TBL] [Abstract][Full Text] [Related]
4. Leg ulcer induced by hydroxycarbamide in sickle cell disease: What is the therapeutic impact?
Soya E; Makowski C; Blaise S
Int Wound J; 2019 Aug; 16(4):897-902. PubMed ID: 30916480
[TBL] [Abstract][Full Text] [Related]
5. Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia.
Nouraie M; Reading NS; Campbell A; Minniti CP; Rana SR; Luchtman-Jones L; Kato GJ; Gladwin MT; Castro OL; Prchal JT; Gordeuk VR
Br J Haematol; 2010 Jul; 150(2):218-25. PubMed ID: 20507315
[TBL] [Abstract][Full Text] [Related]
6. Soluble CD163 levels in children with sickle cell disease.
Moller HJ; Nielsen MJ; Bartram J; Dick MC; Height SE; Moestrup SK; Rees DC
Br J Haematol; 2011 Apr; 153(1):105-10. PubMed ID: 21332709
[TBL] [Abstract][Full Text] [Related]
7. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of clinical severity in treated and untreated sickle cell disease: a comparison by genotypes of a single center cohort and African Americans in the NHANES study.
Njoku F; Zhang X; Shah BN; Machado RF; Han J; Saraf SL; Gordeuk VR
Br J Haematol; 2021 Aug; 194(4):767-778. PubMed ID: 34268729
[TBL] [Abstract][Full Text] [Related]
9. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates.
Novelli EM; Kato GJ; Ragni MV; Zhang Y; Hildesheim ME; Nouraie M; Barge S; Meyer MP; Hassett AC; Gordeuk VR; Gladwin MT; Isenberg JS
Am J Hematol; 2012 Mar; 87(3):326-30. PubMed ID: 22318901
[TBL] [Abstract][Full Text] [Related]
10. Proteinuria in adults with sickle-cell disease: the role of hydroxycarbamide(hydroxyurea) as a protective agent.
Silva Junior GB; Vieira AP; Couto Bem AX; Alves MP; Meneses GC; Martins AM; Araújo SM; Libório AV; Daher EF
Int J Clin Pharm; 2014 Aug; 36(4):766-70. PubMed ID: 24934760
[TBL] [Abstract][Full Text] [Related]
11. Serum apelin as a novel non-invasive marker for subclinical cardiopulmonary complications in children and adolescents with sickle cell disease.
Elbarbary NS; Ismail EA; Roushdy A; Fahmy E
Blood Cells Mol Dis; 2016 Mar; 57():1-7. PubMed ID: 26852648
[TBL] [Abstract][Full Text] [Related]
12. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease.
Lobo CL; Pinto JF; Nascimento EM; Moura PG; Cardoso GP; Hankins JS
Br J Haematol; 2013 Jun; 161(6):852-60. PubMed ID: 23590693
[TBL] [Abstract][Full Text] [Related]
13. Interventions for preventing silent cerebral infarcts in people with sickle cell disease.
Estcourt LJ; Kimber C; Hopewell S; Trivella M; Doree C; Abboud MR
Cochrane Database Syst Rev; 2020 Apr; 4(4):CD012389. PubMed ID: 32250453
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea therapy in children severely affected with sickle cell disease.
Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
[TBL] [Abstract][Full Text] [Related]
15. Hydroxycarbamide for sickle-cell anaemia in infancy.
Weatherall DJ
Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
[No Abstract] [Full Text] [Related]
16. Hydroxyurea in Pediatric Patients With Sickle Cell Disease: What Nurses Need to Know.
Rees AL
J Pediatr Oncol Nurs; 2016 Sep; 33(5):339-44. PubMed ID: 26611755
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
18. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
Green NS; Barral S
Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
[TBL] [Abstract][Full Text] [Related]
19. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease.
Vasavda N; Badiger S; Rees D; Height S; Howard J; Thein SL
Br J Haematol; 2008 Nov; 143(4):589-92. PubMed ID: 18764867
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea for the treatment of sickle cell disease.
Segal JB; Strouse JJ; Beach MC; Haywood C; Witkop C; Park H; Wilson RF; Bass EB; Lanzkron S
Evid Rep Technol Assess (Full Rep); 2008 Mar; (165):1-95. PubMed ID: 18457478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
